dual antiplatelet therapy

ESC 2021 | TOMAHAWK: Angiography After Resuscitated Patients from Out-Of-Hospital Cardiac Arrest with No ST Elevation.

What triggered this study was a long unanswered question: should patients successfully resuscitated from an out-of-hospital cardiac arrest presenting a non-STEMI ECG be immediately taken to the cath lab?&nbsp; In response to this question the TOMAHAWK randomized 554 out-of-hospital resuscitated patients without electrocardiographic evidence of ST-segment elevation patients to immediate angiography (n=281) vs intensive care<a href="https://solaci.org/en/2021/08/31/esc-2021-tomahawk-angiography-after-resuscitated-patients-from-out-of-hospital-cardiac-arrest-with-no-st-elevation/" title="Read more" >...</a>

ESC 2021 | ACST-2: CAS vs endarterectomía en pacientes asintomáticos

ESC 2021 | ACST-2: CAS vs Endarterectomy in Asymptomatic Patients

The ACST-2 was designed to compare long-term outcomes of carotid artery stenting (CAS) vs carotid endarterectomy (CEA) in patients with asymptomatic stenosis.&nbsp; Prior to this study we had the German registry including 18,000 patients undergoing CAS and 86,000 receiving CEA between 2014 and 2019. At 30 days, disabling stroke rate was 0.7% for both strategies.<a href="https://solaci.org/en/2021/08/31/esc-2021-acst-2-cas-vs-endarterectomy-in-asymptomatic-patients/" title="Read more" >...</a>

Sangrados mayores en pacientes con AAS más rivaroxabán

AAS vs DAPT post TAVI: Meta-Analysis of Randomized Studies

Aspirin monotherapy (ASA) reduced the combined risk of thrombotic and bleeding events compared against dual antiplatelet therapy (DAPT) in patients receiving transcatheter aortic valve replacement (TAVR). This meta-analysis has only reproduced smaller randomize study outcomes and does not include the OCEAN-TAVI registry, the only one that has shown something different so far.&nbsp; Even though ASA<a href="https://solaci.org/en/2021/06/14/aas-vs-dapt-post-tavi-meta-analysis-of-randomized-studies/" title="Read more" >...</a>

Aspirina o clopidogrel post TAVI: Guías y estudios llenos de contradicciones

Post TAVR Aspirin vs. Clopidogrel: Conflicting Findings and Guidelines

One month ago we shared a meta-analysis stating aspirin (ASA) as the best antiplatelet following TAVR vs. 3 to 6 dual antiplatelet therapy suggested by guidelines.&nbsp; At that time, guideline recommendations appeared obsolete. Several studies had started to support ASA monotherapy as the best antiaggregation scheme after TAVR. However, in the light of this new<a href="https://solaci.org/en/2021/06/04/post-tavr-aspirin-vs-clopidogrel-conflicting-findings-and-guidelines/" title="Read more" >...</a>

EuroPCR 2021 | CELEBRATE-02: Nuevo inhibidor de la glicoproteína IIb IIIa para infartos con ST

EuroPCR 2021 | CELEBRATE-02: Novel Glycoprotein IIb/IIIa Inhibitor for ST-Segment Elevation Infarction

Promising fast subcutaneous administration and a quick and potent antiplatelet effect, here comes a novel glycoprotein IIb/IIa inhibitor called RUC-4. This novel drug was tested in the CELEBRATE-02 study, presented at EuroPCR 2021 and simultaneously published in EuroIntervention. The mean platelet inhibition begins 15&nbsp;minutes after injection and increases with each of the three tested doses<a href="https://solaci.org/en/2021/05/26/europcr-2021-celebrate-02-novel-glycoprotein-iib-iiia-inhibitor-for-st-segment-elevation-infarction/" title="Read more" >...</a>

EuroPCR 2021 | FUTURE II: las plataformas bioabsorbibles vuelven recargadas

EuroPCR 2021 | FUTURE II: Bioresorbable Scaffolds Reloaded

A new sirolimus-eluting bioresorbable scaffold with far thinner struts resulted non inferior to the Xience as to the end point of angiographic in-segment late loss (LL) powered for noninferiority testing. Even though this is a small study with angiographic end points, it might be the first step towards the return of bioresorbable scaffolds.&nbsp; Read also:<a href="https://solaci.org/en/2021/05/26/europcr-2021-future-ii-bioresorbable-scaffolds-reloaded/" title="Read more" >...</a>

CLASP: resultados a 2 años del nuevo dispositivo de reparación Mitral

EuroPCR 2021 | CLASP: 2 Year Outcomes of the New Mitral Valve Repair System

The 2-year outcomes of the transcatheter mitral valve repair system PASCAL have shown high survival and low rehospitalization rates, and durable reduction of mitral valve regurgitation.&nbsp; These results were provided by the CLASP trial, presented during the EuroPCR scientific sessions and simultaneously published in JACC: Cardiovascular Interventions. The PASCAL system (Edwards) has been authorized for<a href="https://solaci.org/en/2021/05/26/europcr-2021-clasp-2-year-outcomes-of-the-new-mitral-valve-repair-system/" title="Read more" >...</a>

ACC 2021 | TALOS-AMI: desescalar luego de 1 mes de ticagrelor a clopidogrel

ACC 2021 | TALOS-AMI: De-escalating from Ticagrelor to Clopidogrel after One Month

After one-month dual antiplatelet therapy (DAPT) with aspirin and ticagrelor, a net clinical benefit was observed when de-escalating to clopidogrel in acute myocardial infarction (AMI) patients treated with PCI.&nbsp; We have discussed the pros and cons of de-escalating from a potent antiplatelets Such as ticagrelor to clopidogrel since the TOPIC&nbsp;presented at EuroPCR in 2017. What<a href="https://solaci.org/en/2021/05/18/acc-2021-talos-ami-de-escalating-from-ticagrelor-to-clopidogrel-after-one-month/" title="Read more" >...</a>

Most read scientific articles of april at solaci.org

The most read scientific articles on interventional cardiology of april

01- Post MI Betablockers for Good? Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration.&nbsp; Read more HERE 02- Thrombocytopenia and Thrombosis May Be Linked to AstraZeneca Vaccine, Analysis Reports This is one of the<a href="https://solaci.org/en/2021/05/07/the-most-read-scientific-articles-on-interventional-cardiology-of-april/" title="Read more" >...</a>

Recomendaciones de la ACC con el nuevo coronavirus

Diagnosis and Treatment of Vaccine-Induced Thrombosis

Cerebral venous sinus thrombosis is an extremely rare manifestation of cerebrovascular disease.&nbsp; In the last few days, this pathology has sadly gained fame due to its association with two vector-based vaccines against SARR COV19.&nbsp; These are Ad26.COV2.S (Johnson &amp; Johnson) and ChAdOx1 nCoV-19 (AstraZeneca). There have not been any reports of thrombosis or thrombocytopenia from<a href="https://solaci.org/en/2021/05/07/diagnosis-and-treatment-of-vaccine-induced-thrombosis/" title="Read more" >...</a>

Top